Clinical Trials Sponsored by Li-jun Ding

Total 454 results

Li-jun Ding

Recruiting

Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency

Premature Ovarian Insufficiency

China
Li-jun Ding

Completed

Effects of UCA-PSCs in Women With POF

Premature Ovarian Failure

China
Li-jun Ding

Unknown

To Study the Effect of Magnetic Activated Sperm Sorting on the Outcome of in Vitro Fertilization-embryo Transplantation (MASS)

Infertility, Male

China
Li-jun Ding

Unknown

Select Embryos by Time-lapse System for Single Embryo Transfer (SETLSSET)

Embryo
Li-kun Chen

Recruiting

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Brain Metastases

China
Jin Li

Not yet recruiting

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Relapsed Ovarian Cancer
Jun Li

Unknown

One Dose Versus Three Weekly Doses of Benzathine Penicillin G for Patients With Early Syphilis

Syphilis

China
Tsung-Ying Li

Recruiting

Vitamin D Deficiency and Body Composition in the Patients With Hemophilia

Hemophilia | Vitamin D Deficiency | Body Composition | Sarcopenia | Osteoporosis | Hemophilic Arthropathy

Taiwan
Jing Li

Unknown

Impact of HMGB1 on Diastolic Dysfunction in Hypertensive Patients

Inflammation | Hypertension | Diastolic Dysfunction
Yanbing Li

Not yet recruiting

Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes

Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients | Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect | 128 Patients Were Randomly Assigned 1:1 | Metformin and Insulin Glargine Combined... and other conditions

China
Yuhong Li

Completed

Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy

Esophageal Squamous Cell Carcinoma

China
Yuhong Li

Completed

Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Yuhong Li

Completed

Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.

Pancreatic Cancer Resectable

China
Li Zhang

Unknown

Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)

Non-small Cell Lung Cancer

China
Jing Li
Nanjing Shihejiyin Technology, Inc.

Recruiting

Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments

Ovarian Cancer Stage IV | Ovarian Cancer Stage III

China
Binkui Li

Recruiting

HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Yanbing Li

Recruiting

Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification (ESTIMATOR)

Diabetes type2

China
Yuhong Li

Completed

Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC

Metastatic Colorectal Cancer

China
Cheng Li

Recruiting

A Theory-based Home-based Multi-component Exercise Training Among Older Adults With Type 2 Diabetes Mellitus

Sarcopenia | Diabetes Mellitus Type 2

China
Yuhong Li

Recruiting

A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis

Metastatic Colorectal Cancer

China
Yuhong Li

Completed

FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma

Advanced Esophageal Carcinoma

China
Yuhong Li

Completed

Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Yuhong Li

Completed

mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Yuhong Li

Completed

Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment (Poetry-1)

Esophageal Squamous Cell Carcinoma

China
Yuhong Li

Completed

Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer

Colorectal Cancer | Chemotherapy-induced Neutropenia

China
Yuhong Li

Completed

S-1 in Combination With Abraxane in Treating Cholangiocarcinoma

Cholangiocarcinoma

China
Yanbing Li

Unknown

A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy

Type 2 Diabetes Mellitus | Peritoneal Dialysis

China
Li-Jen Hsin

Not yet recruiting

Postoperative Pain Management on Uvulopalatopharyngoplasty Patients

Pain, Postoperative | Pain, Acute | Obstructive Sleep Apnea-hypopnea Syndrome
Li Zhang, MD

Not yet recruiting

JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Non-small Cell Lung Cancer

China
Li Zhang, MD

Not yet recruiting

Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations (TOP)

Non-small Cell Carcinoma | EGFR Gene Mutation

China
Li Zhang, MD

Recruiting

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

Small Cell Lung Cancer | Lung Cancer | Durvalumab

China
Li Zhang, MD

Recruiting

Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance (ERSGATR)

The Diagnosis Was ALK Positive NSCLC | Second Generation ALK-TKI is Resistant | Efficacy of Ensatinib in This Subset of Patients

China
Li Zhang, MD

Recruiting

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Nai Liang Li

Completed

Quality Study of Anesthetic Technique on Breast Cancer Surgery (PQSAT)

Postoperative Pain | Satisfaction | Quality of Recovery

Taiwan
Chong Kun Dang Pharmaceutical

Not yet recruiting

A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome (PRISTINE)

Metabolic Syndrome | Essential Hypertension
Chong Kun Dang Pharmaceutical

Recruiting

A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

Androgenetic Alopecia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Not yet recruiting

Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions

Cardiovascular Diseases

Korea, Republic of
Chong Kun Dang Pharmaceutical

Recruiting

Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes

Type2 Diabetes

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evaluate Pharmacokinetic Profiles and Safety of CKD-387 Under Fasting Condition

Endocrine, Nutritional and Metabolic Diseases

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)

Dyslipidemias

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)

Hypertension | Dyslipidemias

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150

Type 2 Diabetes

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 20/1.25mg

Hypertension

Korea, Republic of
Chong Kun Dang Pharmaceutical

Active, not recruiting

Study to Evaluate the Safety and Pharmacokinetics of CKD-379

Type II Diabetes Mellitus

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Pharmacokinetics and Safety/Tolerability of CKD-379

Type II Diabetes Mellitus

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects (CKD-371)

Type II Diabetes Mellitus

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-828 in Healthy Subjects

Hypertension

Korea, Republic of

3

Subscribe